|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
1R21CA208736-01A1
|
$146,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
1R01CA205965-01A1
|
$650,815
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-02
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-04
|
$329,925
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
|
5R01CA185072-04
|
$348,312
|
SEKULIC, ALEKSANDAR
|
MAYO CLINIC ARIZONA
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
|
5R01CA185189-04
|
$483,693
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
2U54CA163068-06
|
$1,656,304
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
3D Models of Immunotherapy
|
1U01CA214369-01
|
$574,412
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-02
|
$44,044
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A comparison of interventions to teach patients skin self-examination
|
5R01CA154908-07
|
$593,036
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A germline variant that predicts and modulates the response of melanoma to immunotherapy
|
1R21CA209309-01A1
|
$198,103
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-09
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-02
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A novel IL-2 biologic and tumor immunity
|
5R21CA195334-02
|
$200,318
|
MALEK, THOMAS
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A novel in vivo model system of melanoma using a human-mouse neural crest cell chimera
|
5F32CA196065-03
|
$59,166
|
WERT, KATHERINE
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-05
|
$336,150
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$524,680
|
Merlino, Glenn
|
CCR (NCI)
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A real-time, cost-effective, accurate UV measurement and sun protection system to prevent and reduce the incidence of sunburn in high-risk consumers.
|
1R44CA224658-01
|
$213,796
|
Meitl, Matthew
|
WEARIFI, INC.
|
|
A research and training program for junior clinicians in treating metastatic mela
|
5K24CA172123-05
|
$156,084
|
KLUGER, HARRIET
|
YALE UNIVERSITY
|
|
A role for AKT2 in BRAFV600E melanoma initiation, progression, and response to therapy
|
5F31CA210312-02
|
$39,784
|
MCREE, SIOBHAN
|
TUFTS UNIVERSITY BOSTON
|
|
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users
|
5K07CA175115-04
|
$137,183
|
STAPLETON, JEROD
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Adaptive regulation of cancer cell fate following oncogene inhibition
|
4R00CA194163-03
|
$249,001
|
FALLAHI-SICHANI, MOHAMMAD
|
UNIVERSITY OF MICHIGAN
|
|
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells
|
5K08CA197966-04
|
$174,960
|
ITO, FUMITO
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,629,581
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
|
5U24CA180921-05
|
$705,863
|
BECICH, MICHAEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
An innate immune checkpoint in cancer immunotherapy
|
1R01CA212376-01A1
|
$455,406
|
ROTHLIN, CARLA
|
YALE UNIVERSITY
|
|
An integrated translational approach to overcome drug resistance
|
1U54CA224068-01
|
$2,500,407
|
CORCORAN, RYAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma
|
5R01CA171666-04
|
$492,128
|
COUPS, ELLIOT
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,094,457
|
Barr, Frederic
|
CCR (NCI)
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$814,201
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma
|
1R01CA205248-01A1
|
$697,579
|
GREEN, DAMIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibodies to melanoma vaccine peptides
|
1R03CA219715-01
|
$80,500
|
SLINGLUFF, CRAIG
|
UNIVERSITY OF VIRGINIA
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$2,592,300
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Area C: Genome-wide identification and targeting of resistance to cancer therapy
|
1R33CA225291-01
|
$1,459,166
|
RUPPIN, EYTAN
|
UNIV OF MARYLAND, COLLEGE PARK
|
|
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells
|
1R03CA205267-01A1
|
$77,312
|
LEE, YONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Assisted Network-based Analysis of Cancer Gene Expression Studies
|
1R03CA216017-01
|
$83,750
|
MA, SHUANGGE
|
YALE UNIVERSITY
|
|
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition
|
1R01CA207913-01A1
|
$363,833
|
DAVILA, EDUARDO
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Automated Image Guidance for Diagnosing Skin Cancer With Confocal Microscopy
|
5R01CA199673-03
|
$619,539
|
RAJADHYAKSHA, MILIND
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Automated Platform for Fixed Tissue Microdissection
|
4R44CA199194-02
|
$747,594
|
KARSTEN, STANISLAV
|
NEUROINDX INC.
|
|
b-catenin in vaccine-induced anti-tumor CD8 T cell immunity
|
5R01CA198105-03
|
$401,456
|
JIANG, AIMIN
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
BACH2 in Melanoma Development and Resistance
|
5K22CA197058-02
|
$177,344
|
KARRETH, FLORIAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Basic and Preclinical Animal Models in support of Cancer and HIV-AIDS Research
|
ZIG BC 010856
|
$14,497,944
|
Custer, Mary
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|